세계의 비경구 영양제 시장 보고서 :영양 유형, 최종사용자, 지역별(2024-2032년)

The global parenteral nutrition market size reached US$ 7.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.2 Billion by 2032, exhibiting a growth rate (CAGR) of 5.9% during 2024-2032.

Parenteral nutrition (PN), or intravenous feeding, offers liquid nutrients like fats, proteins, vitamins, minerals, carbohydrates, and electrolytes. It is a part of specialized nutritional therapy that providing nutritional support to patients who are unable to utilize their gastrointestinal tract. It aids in preventing malnutrition and maintaining energy, hydration, and strength levels. As a result, it is widely used among patients who are suffering from cancer, Crohn's disease, short bowel syndrome, ischemic bowel disease, and abnormal bowel function.

Parenteral Nutrition Market Trends:

The rising prevalence of malnutrition, growing natality rate, and increasing premature births are among the primary factors catalyzing the demand for PN around the world. Moreover, there is a considerable rise in the number of individuals experiencing pediatric disorders, such as asthma, leukemia, tuberculosis, bronchitis, chickenpox, and anemia. This, along with the rising geriatric population, which is relatively more prone to chronic diseases, is also influencing the demand for PN products positively. Furthermore, the growing consumption of fast food has resulted in the growing instances of non-communicable diseases like hypertension, diabetes, obesity, and other metabolic disorders. This, in confluence with the rising incidences of hepatic insufficiency, renal insufficiency and protein-energy malnutrition, is increasing the consumption of amnio acid-rich and parenteral products. The market is further driven by significant improvements in the PN, such as lipid emulsions optimizations and utilization of indirect calorimetry. Some of the other factors, such as increasing expenditure on the overall development of the healthcare sector by the governing agencies and private entities of several countries and rising adoption of PN products by the healthcare sector, are anticipated to strengthen the market growth across the globe.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global parenteral nutrition market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on nutrient type and end user.

Breakup by Nutrient Type:

Carbohydrates

Lipid Emulsion

Single Dose Amino Acid Solution

Trace Elements

Vitamins and Minerals

Breakup by End User:

Hospitals

Clinics

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Aculife Healthcare Private Limited, B. Braun Melsungen AG, Baxter International Inc., Fresenius SE & Co. KGaA, Grifols S.A., Otsuka Pharmaceutical Factory Inc., Pfizer Inc. and Servona GmbH.

Key Questions Answered in This Report

• 1. How big is the global parenteral nutrition market?
• 2. What is the expected growth rate of the global parenteral nutrition market during 2024-2032?
• 3. What are the key factors driving the global parenteral nutrition market?
• 4. What has been the impact of COVID-19 on the global parenteral nutrition market?
• 5. What is the breakup of the global parenteral nutrition market based on the nutrient type?
• 6. What is the breakup of the global parenteral nutrition market based on the end user?
• 7. What are the key regions in the global parenteral nutrition market?
• 8. Who are the key players/companies in the global parenteral nutrition market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Parenteral Nutrition Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Nutrient Type

• 6.1 Carbohydrates
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Lipid Emulsion
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Single Dose Amino Acid Solution
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Trace Elements
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Vitamins and Minerals
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast

7 Market Breakup by End User

• 7.1 Hospitals
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Clinics
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Others
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 United States
    • 8.1.1.1 Market Trends
    • 8.1.1.2 Market Forecast
  • 8.1.2 Canada
    • 8.1.2.1 Market Trends
    • 8.1.2.2 Market Forecast
• 8.2 Asia-Pacific
  • 8.2.1 China
    • 8.2.1.1 Market Trends
    • 8.2.1.2 Market Forecast
  • 8.2.2 Japan
    • 8.2.2.1 Market Trends
    • 8.2.2.2 Market Forecast
  • 8.2.3 India
    • 8.2.3.1 Market Trends
    • 8.2.3.2 Market Forecast
  • 8.2.4 South Korea
    • 8.2.4.1 Market Trends
    • 8.2.4.2 Market Forecast
  • 8.2.5 Australia
    • 8.2.5.1 Market Trends
    • 8.2.5.2 Market Forecast
  • 8.2.6 Indonesia
    • 8.2.6.1 Market Trends
    • 8.2.6.2 Market Forecast
  • 8.2.7 Others
    • 8.2.7.1 Market Trends
    • 8.2.7.2 Market Forecast
• 8.3 Europe
  • 8.3.1 Germany
    • 8.3.1.1 Market Trends
    • 8.3.1.2 Market Forecast
  • 8.3.2 France
    • 8.3.2.1 Market Trends
    • 8.3.2.2 Market Forecast
  • 8.3.3 United Kingdom
    • 8.3.3.1 Market Trends
    • 8.3.3.2 Market Forecast
  • 8.3.4 Italy
    • 8.3.4.1 Market Trends
    • 8.3.4.2 Market Forecast
  • 8.3.5 Spain
    • 8.3.5.1 Market Trends
    • 8.3.5.2 Market Forecast
  • 8.3.6 Russia
    • 8.3.6.1 Market Trends
    • 8.3.6.2 Market Forecast
  • 8.3.7 Others
    • 8.3.7.1 Market Trends
    • 8.3.7.2 Market Forecast
• 8.4 Latin America
  • 8.4.1 Brazil
    • 8.4.1.1 Market Trends
    • 8.4.1.2 Market Forecast
  • 8.4.2 Mexico
    • 8.4.2.1 Market Trends
    • 8.4.2.2 Market Forecast
  • 8.4.3 Others
    • 8.4.3.1 Market Trends
    • 8.4.3.2 Market Forecast
• 8.5 Middle East and Africa
  • 8.5.1 Market Trends
  • 8.5.2 Market Breakup by Country
  • 8.5.3 Market Forecast

9 SWOT Analysis

• 9.1 Overview
• 9.2 Strengths
• 9.3 Weaknesses
• 9.4 Opportunities
• 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

• 11.1 Overview
• 11.2 Bargaining Power of Buyers
• 11.3 Bargaining Power of Suppliers
• 11.4 Degree of Competition
• 11.5 Threat of New Entrants
• 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 Aculife Healthcare Private Limited
    • 13.3.1.1 Company Overview
    • 13.3.1.2 Product Portfolio
  • 13.3.2 B. Braun Melsungen AG
    • 13.3.2.1 Company Overview
    • 13.3.2.2 Product Portfolio
    • 13.3.2.3 SWOT Analysis
  • 13.3.3 Baxter International Inc.
    • 13.3.3.1 Company Overview
    • 13.3.3.2 Product Portfolio
    • 13.3.3.3 Financials
    • 13.3.3.4 SWOT Analysis
  • 13.3.4 Fresenius SE & Co. KGaA
    • 13.3.4.1 Company Overview
    • 13.3.4.2 Product Portfolio
    • 13.3.4.3 Financials
    • 13.3.4.4 SWOT Analysis
  • 13.3.5 Grifols S.A.
    • 13.3.5.1 Company Overview
    • 13.3.5.2 Product Portfolio
    • 13.3.5.3 Financials
  • 13.3.6 Otsuka Pharmaceutical Factory Inc.
    • 13.3.6.1 Company Overview
    • 13.3.6.2 Product Portfolio
    • 13.3.6.3 Financials
    • 13.3.6.4 SWOT Analysis
  • 13.3.7 Pfizer Inc.
    • 13.3.7.1 Company Overview
    • 13.3.7.2 Product Portfolio
    • 13.3.7.3 Financials
    • 13.3.7.4 SWOT Analysis
  • 13.3.8 Servona GmbH
    • 13.3.8.1 Company Overview
    • 13.3.8.2 Product Portfolio